Heart Failure III Registry

Introduction

In 2010 ESC started to collect data of patients with either Chronic or Acute Heart Failure (HF). It was the start of an ambitious ESC programme intending to describe the clinical epidemiology and the diagnostic & therapeutic approaches applied to these patients.

It is admitted that evidence-based medicine represents the most effective means of ensuring that patients receive high-quality care and appropriate pharmacological/non-pharmacological management. A registry able to capture relevant clinical information of patients with HF, including follow-up, would enable to improve the knowledge on epidemiology and outcomes of real-world patients with this clinical condition as well as to assess implementation of ESC HF guidelines and areas for improvement in the quality of care.

Characteristics

More than 45 countries worldwide are taking part in this programme.

The HF programme of ESC is organized in successive registry phases, each phase enrolling approximately 10 000 patients during a specific enrolment period. We are now launching a new phase III of this programme for which enrolment will start soon.

Population

Adult patients with Chronic and Acute HF regardless of Ejection Fraction (EF).

Objectives of the new Phase III HF Registry

The main objectives of the HF III Registry are:

• To assess contemporary patterns of HF management in practice and to assess adherence to the 2016 ESC HF Guidelines, and how these patterns relate to outcomes.
• To collect information on the reasons for under-utilization of evidence-based treatments or under-dosing with respect to treatments and dosages recommended by guidelines.

Other objectives are to:

• Describe the demographic, clinical, and biological baselines characteristics and outcomes of patients with HF, the diagnostic and therapeutic approaches undertaken in the routine practice.
• Assess the outcomes of patients and validate and develop new prognostic predictors of these outcomes.
• Evaluate patterns of HF management and prevalence of clinical profiles, phenotypes and clusters of patients according to ESC guidelines.

Specific attention will be focused on:

• Patients with preserved or mid-range EF.
• Acute HF: clinical course and outcomes.
• Clinically relevant comorbidities frequently associated with HF and impacting patient outcomes.

Registry Organisation

Lars Lund, the Chairman of the registry

Executive Committee, Phase III - HFIII (2019)

Lars H. Lund (Chair) (DK)
Marisa Crespo Leiro (ES)
Petar Seferovis (RS)
Frank Ruschitzka (UK)
Gerasimos Filippatos (GR)
Alexandre Mebazaa (FR)
Massimo Piepoli (UK)
Stefan Anker (DE)
Theresa McDonagh (UK)
Mitja Lainscak (SV)
Aldo Maggioni (IT)

Executive Committee, Phase II (2013 - 2018)

Marisa Crespo Leiro (Chair) (ES)
Alexandre Mebazaa (FR)
Massimo Piepoli (UK)
Stefan Anker (DE)
Gerasimos Filippatos (GR)
Aldo Maggioni (IT)

Executive Committee, Phase 1 (2011-2013)

Aldo Maggioni (Chairman) (IT)
Stefan Anker (DE)
Ulf Dahlström (SE)
Gerasimos Filippatos (GR)
Luigi Tavazzi (IT)
Piotr Ponikowski (PL)
Faiez Zannad (TN)

Executive Committee, Pilot Phase (2010-2011)

Aldo Maggioni (Chairman) (IT)
Ulf Dahlström (SE)
Gerasimos Filippatos (GR)
Luigi Tavazzi (IT)
Faiez Zannad (TN)

Steering Committee

A Registry Steering Committee is composed of one National Coordinator per participating country. The National Cardiac Societies are responsible for the selection of the national coordinators who are in charge of the registry implementation and running of the registry in their respective countries.